SEC Filings
Delcath's HEPZATO Treatment Volume Grows About 72% As Quarterly Profit Reaches $7 Million
The liver-cancer treatment company raised its 2026 sales outlook to $115 million–$117 million while spending more on trials and expansion.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
The liver-cancer treatment company raised its 2026 sales outlook to $115 million–$117 million while spending more on trials and expansion.
Earnings
Common-shareholder profit rose 59%, helped by an IAA tax refund, while adjusted earnings per share increased 11%.
Earnings
Lower expenses narrowed the net loss, while Quanterix tightened its annual sales outlook and expanded Alzheimer’s testing partnerships.
SEC Filings
ZYNLONTA sales rose to $21 million from $15.8 million, while lower research costs helped reduce operating expenses by 24%.
SEC Filings
Management expects $45 million–$60 million in annual savings by year-end 2027 as it adds four drugs to its hospital sales platform.
Earnings
Third-quarter revenue rose 22.1% to $638.3 million, while Digital Health sales grew and its adjusted earnings measure declined.
SEC Filings
The experimental cancer-drug developer expects its $442.3 million in cash and investments to cover operations into the first half of 2029.
SEC Filings
Common-share sales funded both the Stretch repurchases and $81.9 million in bitcoin purchases, while the company also paid preferred dividends.
SEC Filings
The Tubi chief will succeed Jennifer Witz in January, with a $2.6 million salary and a $10 million sign-on stock award.
Earnings
Management expects the proceeds and existing cash resources to cover operations and capital spending into late fourth quarter 2027.
SEC Filings
The financing carries a 9.35% minimum interest rate and pledges substantially all assets, including intellectual property.
SEC Filings
AN2 expects its funds to last into 2029, with enrollment in its global blood-cancer trial expected by year-end.